Date:May 9,2022				
Your Name:Zizheng Song				
Manuscript Title:_ Two cases of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S				
benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy				
Manuscript number (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	Time frame: Since the initial _ X _None	pranning of the work
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ XNone	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	_ XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	V N	
11	Stock or stock options	_ XNone	
12	Pacaint of aguinment	V None	
12	Receipt of equipment, materials, drugs, medical	_ XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
	Please summarize the above conflict of interest in the following box: Zizheng Song declares none of conflict of interest.		

Date:May 9,2022			
Your Name: Guanying Ren			
Manuscript Title: Two cases of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S			
benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy			
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ X _None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	G ,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or	_ XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	_ ^NUITE	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ XNone	
10	5 · · · · · ·		
12	Receipt of equipment, materials, drugs, medical	_ XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	Please summarize the above conflict of interest in the following box:		
	Guanying Ren declares none of conflict of interest.		

Date:May 9,2022				
Your Name:Ling Hu				
Manuscript Title: Two cases of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S				
benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy				
Manuscript number (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ X _None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	No time illine for this term.		
		Time frame, nect	26 months
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending	XNone		
	meetings and/or travel			
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	_ XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	_ XNone		
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
		_ XNone		
12	Receipt of equipment,	X None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	_ XNone		
	financial interests			
5 .		(1)	L. C. L.	
Ple	Please summarize the above conflict of interest in the following box:			
	Line Hu deslaves were of souffiet of interest			
	Ling Hu declares none of conflict of interest.			

Date:May 9,2022			
Your Name: Xiaolei Wang			
Manuscript Title:_ Two cases of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S			
benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy			
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

-			
5	Payment or honoraria for	XNone	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	, ,		
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	_ XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	V None	
10	in other board, society,	_ XNone	
	committee or advocacy		
_	group, paid or unpaid		
11	Stock or stock options	_ XNone	
12	Receipt of equipment,	_ XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	Please summarize the above conflict of interest in the following box:		
	Xiaolei Wang declares none of conflict of interest.		

Date:May 9,2022
Your Name: Jin Song
Manuscript Title: Two cases of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S
benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
_			
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
0	Participation on a Data	V Name	
9	Safety Monitoring Board or	_ XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	_ XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ XNone	
12	Receipt of equipment,	_ XNone	
	materials, drugs, medical		
	writing, gifts or other		
12	Services Other financial or non	V Name	
13	Other financial or non- financial interests	XNone	
	illianciai interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	Jin Song declares none of co	unflict of interest	
	Jili Jolig declares none of co	minut of interest.	

Date:May 9,2022			
Your Name: Youchao Jia			
Manuscript Title:_ Two cases of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S			
benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy			
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ X _None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	No time illine for this term.		
		Time frame, nect	26 months
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

			$\overline{}$
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V. v.	
6	Payment for expert	XNone	_
	testimony		
_			
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		\exists
9	Participation on a Data	_ XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ XNone	
12	Receipt of equipment,	_ XNone	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non-	_ X _ None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the following box:	
_			1
	Youchao Jia declares none o	f conflict of interest.	

Date:May 9,2022
Your Name: Guofa Zhao
Manuscript Title: Two cases of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S
benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All account for the con-	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	_ X _None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	26 months
2			36 MONUNS
2	Grants or contracts from	_ XNone	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	V None	
3	noyaities of ficefises	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone	
11	Stock or stock options	_ XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone	
13	Other financial or non- financial interests	_ XNone	
	ase summarize the above co		lowing box:

Date:May 9,2022
Your Name: Aimin Zang
Manuscript Title: Two cases of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S
benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ X _None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	No time illine for this term.		
		Time frame, nect	26 months
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
	-		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ XNone	
12	Receipt of equipment,	_ XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_ XNone	
	financial interests		
		(1)	L. C. L.
PIE	ease summarize the above o	onflict of interest in the fol	lowing box:
	Ainsin Zana da	f anuflish of interest	
	Aimin Zang declares none o	i conflict of interest.	
- 1			

Date:May 9,2022			
Your Name:Haiwei Du			
Manuscript Title: Two cases of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S			
benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy			
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ X _None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	No time illine for this term.		
		Time frame, nect	26 months
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	_ XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	_ XNone		
	in other board, society,			
	committee or advocacy group, paid or unpaid			
11	Stock or stock options	_ XNone		
12	Receipt of equipment,	_ XNone		
	materials, drugs, medical			
	writing, gifts or other			
42	services			
13	Other financial or non-		Burning Rock Biotech, Guangzhou, China	
	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
	Haiwei Du is from Burning Rock Biotech, Guangzhou, China.			

Date:May 9,2022
Your Name:Ying Sun
Manuscript Title:_ Two cases of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S
benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ X _None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	No time illine for this term.		
		Time frame, nect	26 months
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
_	educational events			
6	Payment for expert	XNone		
	testimony			
_				
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	_ XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	_ XNone		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid Stock or stock options			
11	Stock or Stock options	_ XNone		
12	Receipt of equipment,	X None		
12	materials, drugs, medical	_ ^None		
	writing, gifts or other			
	services			
13	Other financial or non-		Burning Rock Biotech, Guangzhou, China	
	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
'	Ying Sun is from Burning Rock Biotech, Guangzhou, China.			

Date:May 9,2022				
Your Name:Xiaopeng Zhao				
Manuscript Title: Two cases of non-small cell lung cancer	patients harboring acquired EGFR T790M-cis-C797S			
benefit from immune checkpoint inhibitor combined with	platinum-based doublet chemotherapy			
Manuscript number (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ X _None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	No time illine for this term.		
		Time frame, nect	26 months
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

,			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V N	
6	Payment for expert testimony	XNone	
	testimony		
7	Command from the U		
7	Support for attending meetings and/or travel	XNone	
	meetings and/or traver		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	_ XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ XNone	
4.5			
12	Receipt of equipment,	_ XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests	_ /	
Ple	Please summarize the above conflict of interest in the following box:		
	Xiaopeng Zhao declares none of conflict of interest.		